Vest Financial LLC Has $1.61 Million Holdings in Gilead Sciences, Inc. $GILD

Key Points

• Vest Financial LLC increased its holdings in Gilead Sciences by 39.3% in the 2nd quarter, bringing the total value to approximately $1.61 million.
• Gilead recently reported earnings per share (EPS) of $2.01 for the last quarter, exceeding analysts' estimates, with revenue hitting $7.08 billion.
• The company also declared a quarterly dividend of $0.79, yielding 2.7%, with a payout ratio of 62.95%.

Vest Financial LLC lifted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 39.3% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 14,472 shares of the biopharmaceutical company's stock after purchasing an additional 4,080 shares during the period. Vest Financial LLC's holdings in Gilead Sciences were worth $1,605,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of GILD. Smallwood Wealth Investment Management LLC acquired a new stake in shares of Gilead Sciences in the 1st quarter valued at $25,000. Activest Wealth Management lifted its stake in shares of Gilead Sciences by 2,837.5% in the 1st quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 227 shares during the last quarter. Goodman Advisory Group LLC acquired a new stake in shares of Gilead Sciences in the 1st quarter valued at $29,000. Colonial Trust Advisors lifted its stake in shares of Gilead Sciences by 304.3% in the 1st quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company's stock valued at $32,000 after purchasing an additional 213 shares during the last quarter. Finally, Core Alternative Capital lifted its stake in shares of Gilead Sciences by 370.8% in the 1st quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company's stock valued at $34,000 after purchasing an additional 241 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company's stock.

Gilead Sciences Stock Up 0.2%

Shares of GILD opened at $118.48 on Wednesday. The company has a 50-day simple moving average of $114.84 and a 200-day simple moving average of $110.35. The firm has a market capitalization of $147.01 billion, a P/E ratio of 23.60, a P/E/G ratio of 0.80 and a beta of 0.34. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. Gilead Sciences, Inc. has a 52 week low of $84.80 and a 52 week high of $121.83.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, beating analysts' consensus estimates of $1.96 by $0.05. The business had revenue of $7.08 billion during the quarter, compared to analyst estimates of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The firm's revenue for the quarter was up 1.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, equities research analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, September 29th. Investors of record on Monday, September 15th were paid a $0.79 dividend. The ex-dividend date of this dividend was Monday, September 15th. This represents a $3.16 dividend on an annualized basis and a yield of 2.7%. Gilead Sciences's payout ratio is presently 62.95%.

Wall Street Analyst Weigh In

Several research firms recently issued reports on GILD. UBS Group lifted their price objective on shares of Gilead Sciences from $108.00 to $112.00 and gave the company a "neutral" rating in a research note on Friday, August 8th. Daiwa Capital Markets raised shares of Gilead Sciences from a "neutral" rating to an "outperform" rating and set a $128.00 target price for the company in a research report on Tuesday, August 19th. JPMorgan Chase & Co. boosted their target price on shares of Gilead Sciences from $135.00 to $145.00 and gave the stock an "overweight" rating in a research report on Tuesday, September 16th. Daiwa America raised shares of Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, August 19th. Finally, Royal Bank Of Canada boosted their target price on shares of Gilead Sciences from $98.00 to $100.00 and gave the stock a "sector perform" rating in a research report on Wednesday, October 8th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, Gilead Sciences currently has a consensus rating of "Moderate Buy" and an average target price of $118.08.

Insider Activity at Gilead Sciences

In related news, insider Johanna Mercier sold 3,000 shares of the company's stock in a transaction dated Monday, September 15th. The shares were sold at an average price of $113.57, for a total value of $340,710.00. Following the sale, the insider owned 113,193 shares of the company's stock, valued at $12,855,329.01. The trade was a 2.58% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Daniel Patrick O'day sold 10,000 shares of the company's stock in a transaction dated Monday, September 29th. The shares were sold at an average price of $111.66, for a total transaction of $1,116,600.00. Following the completion of the sale, the chief executive officer directly owned 591,203 shares in the company, valued at approximately $66,013,726.98. The trade was a 1.66% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 66,000 shares of company stock valued at $7,632,100 over the last quarter. 0.27% of the stock is owned by company insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.